Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
On June 10, 2020, the US Food and Drug Administration approved Opdivo (nivolumab) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. 11 June 2020
Biotechnology
The US Food and Drug Administration has approved a label update for Beovu (brolucizumab) to include additional safety information regarding retinal vasculitis and retinal vascular occlusion. 11 June 2020
Biotechnology
A new “BioShield Program” has been launched by Orgenesis, aimed at accelerating the discovery of antibodies to combat viral infections like COVID-19. 11 June 2020
Biotechnology
Danish biotech company Genmab closed 4% higher at the end of Wednesday’s trading after announcing an oncology collaboration with US drugmaker AbbVie. 10 June 2020
Biotechnology
San Diego, USA-based biotech DelMar Pharmaceuticals’ shot up 20% pre-market today, as it revealed the signing of a definitive merger agreement with Adgero Biopharmaceuticals, a privately held biopharmaceutical company focused on the development of its late-stage photodynamic therapy platform for the treatment of serious cutaneous oncology indications. 10 June 2020
Biotechnology
A company formed as a spinout from Cancer Research UK-funded science at The Institute of Cancer Research (ICR), London, has been publicly launched. 10 June 2020
Biotechnology
The European Commission has granted approval for a label extension on Kalydeco (ivacaftor), the only drug approved in Europe to treat the underlying cause of cystic fibrosis. 10 June 2020
Biotechnology
Israel-based biotech RedHill Biopharma has submitted a Clinical Trial Application (CTA) with the Ministry of Health of the Russian Federation for a Phase II/III clinical study evaluating opaganib (trade name Yeliva) in patients hospitalized with severe SARS-CoV-2 infection (the cause of COVID-19) and pneumonia. 10 June 2020
Biotechnology
Japanese pharma major Takeda is to in-license a microbiome remodeling program from Swiss company Debiopharm to develop new treatments for gastrointestinal (GI) disorders. 10 June 2020
Biotechnology
Complementing its pioneering work on a COVID-19 vaccine, British drugmaker AstraZeneca has announced progress in the development of an antibody cocktail to treat infected people. 10 June 2020
Biotechnology
Shares of Oxford, UK based e-therapeutics (ere up 5.7% at 18.15 pence by late morning, after the company revealed a collaboration agreement with Belgium’s Galapagos to identify new therapeutic approaches to modulate a specific mechanism involved in idiopathic pulmonary fibrosis (IPF) and potentially in other fibrotic indications. 10 June 2020
Biotechnology
The Phase III KEYNOTE-361 trial evaluating Keytruda (pembrolizumab), in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not meet its pre-specified dual primary endpoints of overall survival (OS) or progression-free survival (PFS), compared with standard of care chemotherapy. 10 June 2020
Biotechnology
Another major drug trial for a possible COVID-19 therapeutic is to launch in the UK, testing namilumab (IZN-101), an antibody currently in a Phase IIb study in rheumatoid arthritis. 10 June 2020
Biotechnology
The recognition of the existence of certain orphan or rare diseases has been a step forward for many patients around the world, though to what extent they feel acknowledged and supported can depend on where they live. 9 June 2020
Biotechnology
Japanese conglomerate Fujifilm Corp is to invest 100 billion yen ($928 million) in the expansion of its contract development and manufacturing organization (CDMO) in Denmark. 9 June 2020
Biotechnology
In a second major deal within three months for the Oxford University, UK, biotech spinout Evox Therapeutics, the company today announced a research collaboration and license agreement with Eli Lilly to leverage Evox’ proprietary DeliverEX platform. 9 June 2020
Biotechnology
Spanish drugmaker PharmaMar and Taiwanese company TTY Biopharm have announced an exclusive licensing agreement for the import, use, marketing, sale and distribution of the marine-derived anticancer drug Yondelis (trabectedin) in Taiwan, Hong Kong and Macao. 9 June 2020
Biotechnology
It has been a busy day for oncology collaborations between biotechs in Suzhou, China, and pharma majors in Europe. 9 June 2020
Biotechnology
Picking up on a 2017 option agreement, Australian biotech firm CSL Limited’s Behring unit late Monday said it is acquiring its privately-held Canadian collaboration partner. 9 June 2020
Biotechnology
A new strategic research collaboration between Swiss cancer giant Roche and Chinese biotech Innovent Biologics has sent shares in the latter climbing 4% in Hong Kong. 9 June 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze